Wednesday, February 12, 2025
spot_img

Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers

Information
February 11, 2025

Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers

Information relating to the total number of shares and voting rights comprising the share capital as of January 31, 2025

Date Total number of shares1 comprising the share capital Theoretical number of voting rights2
01/31/2025 179,577,400 179,577,400

*

*        *

SCOR, a leading global reinsurer

 

As a leading global reinsurer, SCOR offers its clients a diversified and innovative range of reinsurance and insurance solutions and services to control and manage risk. Applying “The Art & Science of Risk”, SCOR uses its industry-recognized expertise and cutting-edge financial solutions to serve its clients and contribute to the welfare and resilience of society.

 

The Group generated premiums of EUR 19.4 billion in 2023 and serves clients in around 160 countries from its 35 offices worldwide.

 

For more information, visit: www.scor.com

 

Media Relations
Alexandre Garcia
[email protected]

 

 

Investor Relations
Thomas Fossard
[email protected]

 

 

Follow us on LinkedIn

 

All content published by the SCOR group since January 1, 2024, is certified with Wiztrust. You can check the authenticity of this content at wiztrust.com.


1 Each at a nominal value of EUR 7.8769723
2 The gross number of voting rights is calculated on the basis of all shares carrying voting rights, including shares whose voting rights have been suspended (Art. 223-11 of the General Regulation of the AMF)

Attachment

  • 2025 02 11_SCOR_Information relating to the total number of shares and voting rights Wiztrust

Powered by SlickText.com

Hot this week

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Also entered into collaboration and option agreement with AbbVie...

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary...

P10 Reports Fourth Quarter and Full Year 2024 Earnings Results

Generated Record Quarterly Revenue of $85 Million, a 35%...

Bitdeer Announces January 2025 Production and Operations Update

- First trial batch of SEALMINER A2 air cooled...

Topics

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Also entered into collaboration and option agreement with AbbVie...

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary...

P10 Reports Fourth Quarter and Full Year 2024 Earnings Results

Generated Record Quarterly Revenue of $85 Million, a 35%...

Bitdeer Announces January 2025 Production and Operations Update

- First trial batch of SEALMINER A2 air cooled...

Eminent Closes Acquisition of Celts Project in Nevada

VANCOUVER, British Columbia, Feb. 12, 2025 (GLOBE...

Optiva Launches Agentic AI for Telecom BSS, Powered by Google’s Gemini Models

Award-winning BSS platform now seamlessly incorporates virtual generative AI...
spot_img

Related Articles

Popular Categories

spot_img